3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
262
Specimen Handling
253
pembrolizumab
230
Cyclophosphamide
216
Radiotherapy
204
Nivolumab
168
Cisplatin
161
Carboplatin
145
Biopsy
144
Radiosurgery
128
fludarabine
123
Blood Specimen Collection
116
Gemcitabine
111
Paclitaxel
107
Surveys and Questionnaires
106
Standard of Care
102
venetoclax
94
Dexamethasone
93
Bevacizumab
92
Radiation
87
Rituximab
81
Capecitabine
80
Cytarabine
79
Oxaliplatin
77
Drug Therapy
75
Doxorubicin
75
Ipilimumab
73
durvalumab
70
fludarabine phosphate
69
atezolizumab
68
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
trastuzumab duocarmazine
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled